{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:46:37Z","timestamp":1790289997772,"version":"4.1.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of progression to acute myeloid leukemia. Most patients with MDS are affected by anemia and anemia-related symptoms, which negatively impact their quality of life. While many patients with MDS have lower-risk disease and are managed by existing treatments, there currently is no clear standard of care for many patients. For patients with higher-risk disease, the treatment priority is changing the natural history of the disease by delaying disease progression to acute myeloid leukemia and improving overall survival. However, existing treatments for MDS are generally not curative and many patients experience relapse or resistance to first-line treatment. Thus, there remains an unmet need for new, more effective but tolerable strategies to manage MDS. Recent advances in molecular diagnostics have improved our understanding of the pathogenesis of MDS, and it is becoming clear that the diverse nature of genetic abnormalities that drive MDS demands a complex and personalized treatment approach. This review will discuss some of the challenges related to the current MDS treatment landscape, as well as new approaches currently in development.<\/jats:p>","DOI":"10.1038\/s41375-021-01265-7","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T03:51:51Z","timestamp":1622173911000},"page":"2182-2198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Current challenges and unmet medical needs in myelodysplastic syndromes"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-4941","authenticated-orcid":false,"given":"Anne Sophie","family":"Kubasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin","family":"Homer-Bouthiette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6872-625X","authenticated-orcid":false,"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"1265_CR1","unstructured":"National Cancer Institute. Browse the SEER cancer statistics review 1975-2016. https:\/\/seer.cancer.gov\/csr\/1975_2016\/browse_csr.php?sectionSEL=13&pageSEL=sect_13_table.16#table6. Accessed 22 March 2021."},{"key":"1265_CR2","unstructured":"American Cancer Society. Risk factors for myelodysplastic syndromes. https:\/\/www.cancer.org\/cancer\/myelodysplastic-syndrome\/causes-risks-prevention\/risk-factors.html. Accessed 22 March 2021."},{"key":"1265_CR3","unstructured":"National Cancer Institute. Myelodysplastic syndromes treatment (PDQ\u00ae)\u2013health professional version. https:\/\/www.cancer.gov\/types\/myeloproliferative\/hp\/myelodysplastic-treatment-pdq. Accessed 22 March 2021."},{"key":"1265_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","volume":"35","author":"A Kuendgen","year":"2021","unstructured":"Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021;35:835\u201349.","journal-title":"Leukemia."},{"key":"1265_CR5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/ijms17060838","volume":"17","author":"SA Bannon","year":"2016","unstructured":"Bannon SA, DiNardo CD. Hereditary predispositions to myelodysplastic syndrome. Int J Mol Sci. 2016;17:838.","journal-title":"Int J Mol Sci"},{"key":"1265_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MOH.0000000000000633","volume":"28","author":"LA Godley","year":"2021","unstructured":"Godley LA. Germline mutations in MDS\/AML predisposition disorders. Curr Opin Hematol. 2021;28:86\u201393.","journal-title":"Curr Opin Hematol"},{"key":"1265_CR7","first-page":"136","volume":"2","author":"EN Oliva","year":"2012","unstructured":"Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, et al. Quality of life and physicians\u2019 perception in myelodysplastic syndromes. Am J Blood Res. 2012;2:136\u201347.","journal-title":"Am J Blood Res"},{"key":"1265_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1634\/theoncologist.2010-0199","volume":"16","author":"MA Sekeres","year":"2011","unstructured":"Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, et al. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011;16:904\u201311.","journal-title":"Oncologist."},{"key":"1265_CR9","first-page":"1588","volume":"91","author":"L Malcovati","year":"2006","unstructured":"Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588\u201390.","journal-title":"Haematologica."},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.leukres.2007.10.015","volume":"32","author":"DP Steensma","year":"2008","unstructured":"Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008;32:691\u20138.","journal-title":"Leuk Res"},{"key":"1265_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1365-2141.2003.04272.x","volume":"121","author":"AJ Jansen","year":"2003","unstructured":"Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121:270\u20134.","journal-title":"Br J Haematol"},{"key":"1265_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/17474086.2019.1647778","volume":"12","author":"U Germing","year":"2019","unstructured":"Germing U, Schroeder T, Kaivers J, Kundgen A, Kobbe G, Gattermann N. Novel therapies in low- and high-risk myelodysplastic syndrome. Expert Rev Hematol. 2019;12:893\u2013908.","journal-title":"Expert Rev Hematol"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.amjmed.2012.04.015","volume":"125","author":"JM Foran","year":"2012","unstructured":"Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med. 2012;125:S6\u201313.","journal-title":"Am J Med"},{"key":"1265_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.revmed.2019.12.013","volume":"41","author":"C Mornet","year":"2020","unstructured":"Mornet C, Galinat H, Mingant F, Ianotto JC, Lippert E. Thromboses et thrombopathies dans les syndromes my\u00e9loprolif\u00e9ratifs [Thrombosis and platelet dysfunction in myeloproliferative neoplasms]. Rev Med Interne. 2020;41:319\u201324.","journal-title":"Rev Med Interne"},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820\u20139.","journal-title":"J Clin Oncol"},{"key":"1265_CR16","doi-asserted-by":"crossref","unstructured":"Epstein-Peterson ZD, Spitzer B, McCarter J, McGovern E, Levine RL, Tallman MS De novo myelodysplastic syndromes in patients 20-50 years old characterized by frequent mutations in TP53 and transcription-related genes. Blood. 2019;134:2708.","DOI":"10.1182\/blood-2019-123400"},{"key":"1265_CR17","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616\u201327.","journal-title":"Blood."},{"key":"1265_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ajh.24253","volume":"91","author":"N Gangat","year":"2016","unstructured":"Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91:76\u201389.","journal-title":"Am J Hematol"},{"key":"1265_CR19","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Myelodysplastic syndromes. Version 3. 2021."},{"key":"1265_CR20","doi-asserted-by":"crossref","unstructured":"Banaszak LG, Reinig E, Lasarev M, Mattison RJ. Real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes: the Wisconsin experience. Blood. 2019;134:2146.","DOI":"10.1182\/blood-2019-123676"},{"key":"1265_CR21","doi-asserted-by":"crossref","unstructured":"Ganster C, Schaab R, Shirneshan K, Eder LN, Mies A, Germing U, et al. TP53 status as well as cytogenetic complexity significantly impact on prognosis in myelodysplastic syndromes with complex (\u22653 anomalies) aberrant karyotypes. Blood. 2019;134:3007.","DOI":"10.1182\/blood-2019-126671"},{"key":"1265_CR22","doi-asserted-by":"crossref","unstructured":"Bernard E, Nannya Y, Yoshizato T, Hasserjian RP, Saiki R, Shiozawa Y, et al. TP53 state dictates genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Blood. 2019;134:675.","DOI":"10.1182\/blood-2019-129392"},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496\u2013506.","journal-title":"N Engl J Med"},{"key":"1265_CR24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"1265_CR25","doi-asserted-by":"crossref","unstructured":"Jiang L, Luo Y, Jin J, Tong H. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes. Blood. 2019;134:3008.","DOI":"10.1182\/blood-2019-125660"},{"key":"1265_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241\u20137.","journal-title":"Leukemia"},{"key":"1265_CR27","doi-asserted-by":"crossref","unstructured":"Hong S, Kerr CM, Rybicki L, Visconte V, Durrani J, Awada H, et al. Pattern of somatic mutation changes from diagnosis to relapse following allogeneic hematopoietic cell transplantation (alloHCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Blood. 2019;134:2716.","DOI":"10.1182\/blood-2019-130352"},{"key":"1265_CR28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","volume":"35","author":"JA Kennedy","year":"2017","unstructured":"Kennedy JA, Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol. 2017;35:968\u201374.","journal-title":"J Clin Oncol"},{"key":"1265_CR29","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","volume":"133","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133:1039\u201348.","journal-title":"Blood."},{"key":"1265_CR30","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1097\/HS9.0000000000000162","volume":"2","author":"KS Gotze","year":"2018","unstructured":"Gotze KS, Platzbecker U. Old dogs, new tricks: revisiting immune modulatory approaches for myelodysplastic syndromes. Hemasphere. 2018;2:e162.","journal-title":"Hemasphere"},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.24930","volume":"93","author":"G Montalban-Bravo","year":"2018","unstructured":"Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93:129\u201347.","journal-title":"Am J Hematol"},{"key":"1265_CR32","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood."},{"key":"1265_CR33","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u201388.","journal-title":"Blood."},{"key":"1265_CR34","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","volume":"25","author":"L Malcovati","year":"2007","unstructured":"Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503\u201310.","journal-title":"J Clin Oncol"},{"key":"1265_CR35","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","volume":"96","author":"L Malcovati","year":"2011","unstructured":"Malcovati L, la Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96:1433\u201340.","journal-title":"Haematologica."},{"key":"1265_CR36","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood."},{"key":"1265_CR37","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.leu.2405070","volume":"22","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538\u201343.","journal-title":"Leukemia."},{"key":"1265_CR38","doi-asserted-by":"crossref","unstructured":"Wan BA, Wells RA, Chodirker L, Rockwood K, Geddes M, Zhu N, et al. Prognostic performance of frailty measures in MDS patients treated with hypomethylating agents. Blood. 2019;134:4245.","DOI":"10.1182\/blood-2019-128949"},{"key":"1265_CR39","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/ajh.25234","volume":"93","author":"CB Benton","year":"2018","unstructured":"Benton CB, Khan M, Sallman D, Nazha A, Nogueras Gonzalez GM, Piao J, et al. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018;93:1245\u201353.","journal-title":"Am J Hematol"},{"key":"1265_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/asheducation-2017.1.453","volume":"2017","author":"A Giagounidis","year":"2017","unstructured":"Giagounidis A. Current treatment algorithm for the management of lower-risk MDS. Hematol Am Soc Hematol Educ Program. 2017;2017:453\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1265_CR41","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","volume":"133","author":"U Platzbecker","year":"2019","unstructured":"Platzbecker U. Treatment of MDS. Blood. 2019;133:1096\u2013107.","journal-title":"Blood."},{"key":"1265_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.seminoncol.2011.04.014","volume":"38","author":"DP Steensma","year":"2011","unstructured":"Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011;38:635\u201347.","journal-title":"Semin Oncol"},{"key":"1265_CR43","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bjh.16206","volume":"189","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189:1016\u201327.","journal-title":"Br J Haematol"},{"key":"1265_CR44","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943\u201364.","journal-title":"Blood."},{"key":"1265_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0085-4","volume":"8","author":"DP Steensma","year":"2018","unstructured":"Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018;8:47.","journal-title":"Blood Cancer J."},{"key":"1265_CR46","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","volume":"114","author":"PL Greenberg","year":"2009","unstructured":"Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114:2393\u2013400.","journal-title":"Blood."},{"key":"1265_CR47","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","volume":"5","author":"R Komrokji","year":"2018","unstructured":"Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018;5:e63\u201372.","journal-title":"Lancet Haematol"},{"key":"1265_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140\u201351.","journal-title":"N Engl J Med"},{"key":"1265_CR49","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","volume":"133","author":"P Fenaux","year":"2019","unstructured":"Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133:790\u20134.","journal-title":"Blood."},{"key":"1265_CR50","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","volume":"18","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Germing U, G\u00f6tze KS, Kiewe P, Mayer K, Chromik J, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338\u201347.","journal-title":"Lancet Oncol"},{"key":"1265_CR51","unstructured":"European Medicines Agency. Reblozyl 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/reblozyl#authorisation-details-section. Accessed 22 March 2021."},{"key":"1265_CR52","unstructured":"VIDAZA\u00ae (azacitidine for injection), for subcutaneous or intravenous use [package insert]. Summit, NJ: Celgene Corporation; 2018."},{"key":"1265_CR53","unstructured":"DACOGEN\u00ae (decitabine) for injection, for intravenous use [package insert]. Haarlem, The Netherlands: Pharmachemie B.V. Haarlem; 2018."},{"key":"1265_CR54","unstructured":"European Medicines Agency. Dacogen 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dacogen#authorisation-details-section. Accessed 22 March 2021."},{"key":"1265_CR55","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00277-018-3464-9","volume":"97","author":"H Wang","year":"2018","unstructured":"Wang H, Li Y, Lv N, Li Y, Wang L, Yu L. Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes. Ann Hematol. 2018;97:2025\u201338.","journal-title":"Ann Hematol"},{"key":"1265_CR56","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","volume":"2","author":"M Stahl","year":"2018","unstructured":"Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2:1765\u201372.","journal-title":"Blood Adv"},{"key":"1265_CR57","unstructured":"European Medicines Agency. Revlimid 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/revlimid#product-information-section. Accessed 22 March 2021."},{"key":"1265_CR58","unstructured":"REVLIMID\u00ae (lenalidomide) capsules [package insert]. Summit, NJ: Celgene Corporation; 2019."},{"key":"1265_CR59","doi-asserted-by":"crossref","unstructured":"Lode L, Menard A, Flet L, Richebourg S, Loirat M, Eveillard M, et al. Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica. 2018;103:e143\u20136.","DOI":"10.3324\/haematol.2017.181404"},{"key":"1265_CR60","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","volume":"34","author":"V Santini","year":"2016","unstructured":"Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988\u201396.","journal-title":"J Clin Oncol"},{"key":"1265_CR61","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753\u201362.","journal-title":"Blood."},{"key":"1265_CR62","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00277-018-3466-7","volume":"97","author":"E Schuler","year":"2018","unstructured":"Schuler E, Zadrozny N, Blum S, Schroeder T, Strupp C, Hildebrandt B, et al. Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy. Ann Hematol. 2018;97:2325\u201332.","journal-title":"Ann Hematol"},{"key":"1265_CR63","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/bmt.2017.171","volume":"52","author":"C Scheid","year":"2017","unstructured":"Scheid C, de Wreede L, van Biezen A, Koenecke C, Gohring G, Volin L, et al. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome\/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. Bone Marrow Transpl. 2017;52:1519\u201325.","journal-title":"Bone Marrow Transpl"},{"key":"1265_CR64","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","volume":"32","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249\u201356.","journal-title":"J Clin Oncol"},{"key":"1265_CR65","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood."},{"key":"1265_CR66","doi-asserted-by":"crossref","unstructured":"Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St. Martin A, Bashey A, et al. Allogeneic transplantation for myelodysplastic syndrome in adults over 50 years old using reduced intensity\/non-myeloablative conditioning: haploidentical relative versus matched unrelated donor. Blood. 2019;134:3323.","DOI":"10.1182\/blood-2019-125865"},{"key":"1265_CR67","doi-asserted-by":"crossref","unstructured":"Roberts L, Salit RB, Longo L, Xue E, Summers C, Delaney C, et al. Cord blood transplantation is an effective treatment option in patients with myelodysplastic and myeloproliferative syndromes. Blood. 2019;134:2048.","DOI":"10.1182\/blood-2019-126216"},{"key":"1265_CR68","doi-asserted-by":"crossref","unstructured":"Wang W, Auer P, Spellman SR, Carlson KSB, Nazha A, Maiers M, et al. Epigenomic signatures in myelodysplastic syndrome patients as predictors of donor compatibility and transplant outcome. Blood. 2019;134:4557.","DOI":"10.1182\/blood-2019-127124"},{"key":"1265_CR69","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","volume":"104","author":"CS Cutler","year":"2004","unstructured":"Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579\u201385.","journal-title":"Blood."},{"key":"1265_CR70","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.bbmt.2019.03.011","volume":"25","author":"T Schroeder","year":"2019","unstructured":"Schroeder T, Wegener N, Lauseker M, Rautenberg C, Nachtkamp K, Schuler E, et al. Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transpl. 2019;25:1550\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1265_CR71","doi-asserted-by":"crossref","unstructured":"Stein EM, Latremouille-Viau D, Joseph GJ, Shi S, Guerin A, Wu EQ, et al. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Blood. 2019;134:3495.","DOI":"10.1182\/blood-2019-124878"},{"key":"1265_CR72","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/leu.2015.115","volume":"29","author":"T Bernal","year":"2015","unstructured":"Bernal T, Martinez-Camblor P, Sanchez-Garcia J, de Paz R, Luno E, Nomdedeu B, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29:1875\u201381.","journal-title":"Leukemia"},{"key":"1265_CR73","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","volume":"117","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403\u201311.","journal-title":"Blood"},{"key":"1265_CR74","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.1158\/1078-0432.CCR-17-1423","volume":"23","author":"CF Craddock","year":"2017","unstructured":"Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, et al. Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature. Clin Cancer Res. 2017;23:6430\u201340.","journal-title":"Clin Cancer Res"},{"key":"1265_CR75","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705\u201312.","journal-title":"Blood"},{"key":"1265_CR76","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","volume":"118","author":"T Braun","year":"2011","unstructured":"Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118:3824\u201331.","journal-title":"Blood"},{"key":"1265_CR77","doi-asserted-by":"crossref","unstructured":"Henry DH, Glaspy J, Harrup RA, Mittelman M, Zhou A, Carraway HE, et al. Oral roxadustat demonstrates efficacy in anemia secondary to lower-risk myelodysplastic syndrome irrespective of ring sideroblasts and baseline erythropoietin levels. Blood. 2020;136:1277.","DOI":"10.1182\/blood-2020-142499"},{"key":"1265_CR78","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/JCO.20.01895","volume":"39","author":"DP Steensma","year":"2021","unstructured":"Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39:48\u201356.","journal-title":"J Clin Oncol"},{"key":"1265_CR79","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","volume":"4","author":"EN Oliva","year":"2017","unstructured":"Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4:e127\u201336.","journal-title":"Lancet Haematol"},{"key":"1265_CR80","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1038\/leu.2014.253","volume":"28","author":"U Platzbecker","year":"2014","unstructured":"Platzbecker U, Sekeres MA, Kantarjian H, Giagounidis A, Mufti GJ, Jia C, et al. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial. Leukemia. 2014;28:2418\u201321.","journal-title":"Leukemia."},{"key":"1265_CR81","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","volume":"5","author":"M Mittelman","year":"2018","unstructured":"Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;5:e34\u201343.","journal-title":"Lancet Haematol"},{"key":"1265_CR82","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/bjh.14792","volume":"178","author":"P Fenaux","year":"2017","unstructured":"Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, et al. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017;178:906\u201313.","journal-title":"Br J Haematol"},{"key":"1265_CR83","unstructured":"Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman L, et al. A phase III placebo-controlled trial of CC-486 in patients with red blood cell transfusion-dependent (RBC-TD) anemia and thrombocytopenia due to IPSS lower-risk myelodysplastic syndromes (LR-MDS). Presented at: European Hematology Association 25th Annual Congress; 11\u201321 June 2020; Virtual."},{"key":"1265_CR84","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2017.21","volume":"31","author":"EA Eksioglu","year":"2017","unstructured":"Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31:2172\u201380.","journal-title":"Leukemia."},{"key":"1265_CR85","doi-asserted-by":"crossref","unstructured":"Smith V, Eckard S, Rettig MP, Gehrs LN, Guenot J, Wei S, et al. AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients. Presented at: American Association for Cancer Research Annual Meeting; 27\u201328 April 2020 and 22\u201324 June 2020; Philadelphia, PA. Abstract 5699.","DOI":"10.1158\/1538-7445.AM2020-5699"},{"key":"1265_CR86","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3324\/haematol.2018.207118","volume":"104","author":"M Sebert","year":"2019","unstructured":"Sebert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica 2019;104:1565\u201371.","journal-title":"Haematologica"},{"key":"1265_CR87","doi-asserted-by":"crossref","unstructured":"Savona MR, McCloskey JK, Griffiths EA, Yee KWL, Al-Kali A, Zeidan AM, et al. Clinical efficacy and safety of oral decitabine\/cedazuridine in 133 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Blood. 2020;136:1230.","DOI":"10.1182\/blood-2020-133855"},{"key":"1265_CR88","unstructured":"Sekeres MA, Watts JM, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, et al. Efficacy and safety of pevonedistat plus azacitidine vs azacitidine alone in higher-risk myelodysplastic syndromes (MDS) from study P-2001 (NCT02610777). Blood. 2020;136:653."},{"key":"1265_CR89","doi-asserted-by":"crossref","unstructured":"Richard-Carpentier G, DeZern AE, Takahashi K, Konopleva MY, Loghavi S, Masarova L, et al. Preliminary results from the phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). Blood. 2019;134:678.","DOI":"10.1182\/blood-2019-130501"},{"key":"1265_CR90","doi-asserted-by":"crossref","unstructured":"Foran JM, DiNardo CD, Watts JM, Stein EM, De Botton S, Fathi AT, et al. Ivosidenib (AG-120) in patients with IDH1-mutant relapsed\/refractory myelodysplastic syndrome: updated enrollment of a phase 1 dose escalation and expansion study. Blood. 2019;134:4254.","DOI":"10.1182\/blood-2019-123946"},{"key":"1265_CR91","doi-asserted-by":"crossref","unstructured":"Cortes JE, Wang ES, Watts JM, Lee S, Baer MR, Dao KH, et al. Olutasidenib (FT-2102) induces rapid remissions in patients with IDH1-mutant myelodysplastic syndrome: results of phase 1\/2 single agent treatment and combination with azacitidine. Blood. 2019;134:674.","DOI":"10.1182\/blood-2019-124360"},{"key":"1265_CR92","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Pollyea DA, Garcia JS, Brunner A, Roncolato F, Borate U, et al. A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome. Blood. 2019;134:565.","DOI":"10.1182\/blood-2019-124994"},{"key":"1265_CR93","doi-asserted-by":"crossref","unstructured":"Gerds AT, Scott BL, Greenberg PL, Khaled SK, Lin TL, Pollyea DA, et al. PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis. Blood. 2018;132:466.","DOI":"10.1182\/blood-2018-99-118577"},{"key":"1265_CR94","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, Alvarado Y, et al. A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS). Blood. 2018;132:465.","DOI":"10.1182\/blood-2018-99-118948"},{"key":"1265_CR95","doi-asserted-by":"crossref","unstructured":"Brunner AM, Esteve J, Porkka K, Knapper S, Vey N, Scholl S, et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): updated results from a phase 1b study. Blood. 2020;136:657.","DOI":"10.1182\/blood-2020-136855"},{"key":"1265_CR96","doi-asserted-by":"crossref","unstructured":"Navada SC, Garcia-Manero G, Atallah EL, Rajeh MN, Shammo JM, Griffiths EA, et al. Phase II study of oral rigosertib combined with azacitidine (AZA) as first line therapy in patients (Pts) with higher-risk myelodysplastic syndromes (HR-MDS). Blood. 2019;134:566.","DOI":"10.1182\/blood-2019-131676"},{"key":"1265_CR97","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Navada SC, Fenaux P, Zbyszewski PS, Adesanya AR, Azarnia N, et al. Phase 3, multi-center, international, randomized, double-blind, placebo controlled study of oral rigosertib + injectable azacitidine (AZA) versus injectable azacitidine in treatment-naive patients with higher-risk myelodysplastic syndrome (HR-MDS). Blood. 2019;134:4268.","DOI":"10.1182\/blood-2019-132149"},{"key":"1265_CR98","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","volume":"7","author":"EM Stein","year":"2020","unstructured":"Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020;7:e309\u201319.","journal-title":"Lancet Haematol"},{"key":"1265_CR99","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ajh.25238","volume":"93","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol. 2018;93:1301\u201310.","journal-title":"Am J Hematol"},{"key":"1265_CR100","doi-asserted-by":"crossref","unstructured":"Wei AH, Garcia JS, Borate U, Fong CY, Baer MR, Nolte F, et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-na\u00efve patients with higher-risk myelodysplastic syndrome. Blood. 2019;134:568.","DOI":"10.1182\/blood-2019-124437"},{"key":"1265_CR101","unstructured":"VYXEOS\u00ae (daunorubicin and cytarabine) liposome for injection, for intravenous us [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2021."},{"key":"1265_CR102","unstructured":"Lin TL, Uy GL, Wieduwilt MJ, Newell LF, Stuart RK, Medeiros BC, et al. Subanalysis of patients with secondary acute myeloid leukemia (sAML) with refractory anemia with excess of blasts in transformation (RAEB-t) enrolled in a phase 3 study of CPX-351 versus conventional 7+3 cytarabine and daunorubicin. Blood. 2017;130:1698."},{"key":"1265_CR103","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","volume":"17","author":"G Garcia-Manero","year":"2016","unstructured":"Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:496\u2013508.","journal-title":"Lancet Oncol"},{"key":"1265_CR104","unstructured":"Onconova Therapeutics. Onconova therapeutics announces topline results from the pivotal phase 3 INSPIRE trial. 2020. https:\/\/www.globenewswire.com\/news-release\/2020\/08\/24\/2082504\/0\/en\/Onconova-Therapeutics-Announces-Topline-Results-from-the-Pivotal-Phase-3-INSPIRE-Trial.html. Accessed 22 March 2021."},{"key":"1265_CR105","doi-asserted-by":"publisher","first-page":"204062071984705","DOI":"10.1177\/2040620719847059","volume":"10","author":"A Gil-Perez","year":"2019","unstructured":"Gil-Perez A, Montalban-Bravo G. Management of myelodysplastic syndromes after failure of response to hypomethylating agents. Ther Adv Hematol. 2019;10:2040620719847059.","journal-title":"Ther Adv Hematol"},{"key":"1265_CR106","doi-asserted-by":"crossref","unstructured":"Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013;88:56\u20139.","DOI":"10.1002\/ajh.23345"},{"key":"1265_CR107","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/sj.leu.2403274","volume":"18","author":"LY Shih","year":"2004","unstructured":"Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 2004;18:466\u201375.","journal-title":"Leukemia"},{"key":"1265_CR108","doi-asserted-by":"crossref","unstructured":"Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML). Blood. 2019;134:673.","DOI":"10.1182\/blood-2019-123854"},{"key":"1265_CR109","doi-asserted-by":"crossref","unstructured":"Uy GL, Godwin J, Rettig MP, et al. Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific Dart\u00ae protein, in patients with relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome. Blood. 2017;130:637.","DOI":"10.1182\/blood.V130.Suppl_1.637.637"},{"key":"1265_CR110","doi-asserted-by":"crossref","unstructured":"Kubasch AS, Peterlin P, Cluzeau T, G\u00f6tze KS, Sockel K, Teipel R, et al. Efficacy and safety of bemcentinib in patients with myelodysplastic syndromes or acute myeloid leukemia failing hypomethylating agents. Blood. 2020;136:1287.","DOI":"10.1182\/blood-2020-140240"},{"key":"1265_CR111","doi-asserted-by":"crossref","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39:1584\u201394.","DOI":"10.1200\/JCO.20.02341"},{"key":"1265_CR112","unstructured":"Aprea Therapeutics. Aprea Therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). 2020. https:\/\/ir.aprea.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3. Accessed 22 March 2021."},{"key":"1265_CR113","doi-asserted-by":"publisher","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","volume":"10","author":"LA Carvajal","year":"2018","unstructured":"Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018;10:eaao3003.","journal-title":"Sci Transl Med"},{"key":"1265_CR114","doi-asserted-by":"crossref","unstructured":"Sallman DA, Asch AS, Al Malki MM, Lee DJ, Donnellan WB, Marcucci G, et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results. Blood. 2019;134:569.","DOI":"10.1182\/blood-2019-126271"},{"key":"1265_CR115","doi-asserted-by":"crossref","unstructured":"Ritchie EK, Miah SK, Lee S, Curcio T, Desai P, Ball J, et al. CPX-351 as first intensive therapy for elderly patients with AML. Blood. 2019;134:3858.","DOI":"10.1182\/blood-2019-130263"},{"key":"1265_CR116","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"1265_CR117","doi-asserted-by":"crossref","unstructured":"Cluzeau T, Sebert M, Rahm\u00e9 R, Cuzzubbo S, Walter-petrich A, Lehmann che J, et al. APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A phase 2 study by the groupe Francophone Des My\u00e9lodysplasies (GFM). Blood. 2019;134:677.","DOI":"10.1182\/blood-2019-125579"},{"key":"1265_CR118","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","volume":"21","author":"T Schroeder","year":"2015","unstructured":"Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transpl. 2015;21:653\u201360.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1265_CR119","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MOH.0000000000000464","volume":"25","author":"RM Shapiro","year":"2018","unstructured":"Shapiro RM, Kim DDH. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. Curr Opin Hematol. 2018;25:425\u201332.","journal-title":"Curr Opin Hematol"},{"key":"1265_CR120","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/jcm6090087","volume":"6","author":"GW Roloff","year":"2017","unstructured":"Roloff GW, Lai C, Hourigan CS, Dillon LW. Technical advances in the measurement of residual disease in acute myeloid leukemia. J Clin Med. 2017;6:87.","journal-title":"J Clin Med"},{"key":"1265_CR121","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.bbmt.2018.05.011","volume":"24","author":"C Rautenberg","year":"2018","unstructured":"Rautenberg C, Pechtel S, Hildebrandt B, Betz B, Dienst A, Nachtkamp K, et al. Wilms\u2019 tumor 1 gene expression using a standardized european LeukemiaNet-certified assay compared to other methods for detection of minimal residual disease in myelodysplastic syndrome and acute myelogenous leukemia after allogeneic blood stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:2337\u201343.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1265_CR122","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19:1668\u201379.","journal-title":"Lancet Oncol"},{"key":"1265_CR123","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","volume":"128","author":"M Pfeilstocker","year":"2016","unstructured":"Pfeilstocker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sole F, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128:902\u201310.","journal-title":"Blood"},{"key":"1265_CR124","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1182\/asheducation-2017.1.447","volume":"2017","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC. Uncoding the genetic heterogeneity of myelodysplastic syndrome. Hematol Am Soc Hematol Educ Program. 2017;2017:447\u201352.","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01265-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:42:14Z","timestamp":1684618934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01265-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":124,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01265-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"UP reports research funding and honoraria from Amgen, Celgene, Janssen, and Novartis. ASK reports consultancy fees from Amgen, Novartis, and Takeda. CH-B has no conflicts of interest to disclose. TP reports research funding from Jazz Pharmaceuticals and consultancy fees from AbbVie and Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}